{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:18:34Z","timestamp":1791119914013,"version":"4.1.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review aims to describe clinical and pathological features, prognosis and treatment in patients with anti-HMGCR antibody positive immune-mediated necrotizing myopathy (HMGCR-IMNM) based on recent findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Using advances in diagnostic modalities that can confirm the presence of anti-HMGCR antibody, the clinical and pathological manifestations of HMGCR-IMNM were found to be broader than previously reported. Although only a small percentage of HMGCR-IMNM patients present with atypical manifestations, some of these patients show slow disease progression and clinical symptoms, which are similar to those of limb-girdle muscular dystrophies. Other atypical HMGCR-IMNM patients have skin conditions similar to dermatomyositis-like skin rush or dermatological presentations of Jessner-Kanoff disease or cutaneous lymphoma, whose pathological changes including CD8-positive and bcl-2-positive lymphocytic accumulations, similar to Jessner-Kanoff lymphocytic infiltration of skin or low-grade cutaneous lymphoma, which are observed in muscle and skin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Anti-HMGCR autoantibodies define unique populations of IMNM patients. Recent studies have revealed that clinicopathological manifestations of HMGCR-IMNM, especially extramuscular symptoms and pathological manifestations, are more common than previously recognized.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000832","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T02:01:23Z","timestamp":1630288883000},"page":"554-562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Anti-HMGCR myopathy: clinical and histopathological features, and prognosis"],"prefix":"10.1097","volume":"33","author":[{"given":"Takashi","family":"Kurashige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","article-title":"Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort","volume":"74","author":"Dobloug","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","article-title":"Human autoantibodies reactive with the signal-recognition particle","volume":"83","author":"Reeves","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune- mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"A new classification of autoimmune myositis","volume":"69","author":"Sene\u0301cal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","article-title":"Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity","volume":"76","author":"Pinal-Fernandez","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e5694","DOI":"10.1097\/MD.0000000000005694","article-title":"Atorvastatin-induced necrotizing autoimmune myositis: an emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype","volume":"96","author":"Troyanov","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"R19-20250526","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2018","journal-title":"J Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of antisignal recognition protein and anti3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP(+) and anti-HMGCR(+) myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1212\/NXI.0000000000000523","article-title":"Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy","volume":"6","author":"Mohassel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnen\/nlaa006","article-title":"Anti-HMGCR antibody-positive myopathy shows Bcl-2-positive inflammation and lymphocytic accumulations","volume":"79","author":"Kurashige","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"adv00415","DOI":"10.2340\/00015555-3645","article-title":"Unusual skin involvement in statin-induced anti-HMGCR immune-mediated necrotizing myopathy","volume":"101","author":"Scard","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"R28-20250526","article-title":"Statin-associated anti-HMGCR immune- mediated necrotizing myopathy with dermatomyositis-like features: a case report","volume":"8","author":"Lim","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"R29-20250526","article-title":"Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy","author":"Hou","year":"2021","journal-title":"J Neurol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0021-9258(18)89764-2","article-title":"Domain structure of 3-hydroxy- 3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum","volume":"260","author":"Liscum","year":"1985","journal-title":"J Biol Chem"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018\u200aAHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/ATVBAHA.111.240754","article-title":"Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death","volume":"32","author":"Nagashima","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0022-510X(92)90273-N","article-title":"Experimental simvastatin-induced myopathy in rabbits","volume":"113","author":"Nakahara","year":"1992","journal-title":"J Neurol Sci"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-5793(98)01320-9","article-title":"HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidyl inositol 3-kinase pathway","volume":"438","author":"Nakagawa","year":"1998","journal-title":"FEBS Lett"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-5793(99)00188-X","article-title":"Role of tyrosine phosphorylation of phspholipase C (1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts","volume":"446","author":"Mutoh","year":"1999","journal-title":"FEBS Lett"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti3-hydroxy- 3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with antisignal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated Diagnosis Project for Inflammatory Myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti 3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of anti3-hydroxy- 3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1\u221707:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti3-hydroxy-3-methylglutaryl- coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatology"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0000000000003160","article-title":"HLA-DRB1 alleles in immune-mediated necrotizing myopathy","volume":"87","author":"Ohnuki","year":"2016","journal-title":"Neurology"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1\u221711:01 in antihydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.50.3.764","article-title":"Paraneoplastic necrotizing myopathy: clinical and pathological features","volume":"50","author":"Levin","year":"1998","journal-title":"Neurology"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"R59-20250526","first-page":"557","article-title":"Paraneoplastic necrotizing myopathy presenting as severe muscle weakness in a patient with small-cell lung cancer: successful response to chemoradiation therapy","volume":"9","author":"Vu","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects asso- ciated with anti3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10067-017-3831-2","article-title":"Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort","volume":"37","author":"Waters","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"105871","DOI":"10.1016\/j.clineuro.2020.105871","article-title":"Anti-HMGCR myopathy mimicking limb-girdle muscular dystrophy and the response to Rituximab","volume":"194","author":"Idiculla","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1212\/NXI.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","article-title":"Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies","volume":"30","author":"Fischer","year":"2019","journal-title":"Brain Pathol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.26608","article-title":"Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy","volume":"60","author":"Girolamo","year":"2019","journal-title":"Muscle Nerve"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.semarthrit.2020.02.009","article-title":"Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI","volume":"50","author":"Landon-Cardinal","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/WCO.0b013e328364e9d9","article-title":"Acquired necrotizing myopathies","volume":"26","author":"Allenbach","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","article-title":"Use of proprotein convertase Subtilisin\/Kexin Type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series","volume":"71","author":"Tiniakou","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:00:17Z","timestamp":1748296817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000832","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}